StreetInsider.com News Articles

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 15, 2026 to 13 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 20 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,676 time-based restricted

Madrigal Pharmaceuticals adds J&J executive to its board

Wed, 12 Aug 2026 08:00:58 -0400

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its board of directors, the company announced Aug. 12, 2026.

Dr. Reed currently serves as Executive Vice President of Innovative Medicine, Research & Development at Johnson & Johnson, where he leads research and development across oncology, immunology, and neuroscience. He is also a member of Johnson & Johnson's Executive Committee.

Before joining Johnson & Johnson in April 2023, Dr. Reed held executive leadership positions at Sanofi and Roche, serving on their respective executive committees. He previously served as President and Chief Executive Officer of Sanford-Burnham Medical Research Institute, now

Madrigal Pharmaceuticals adds J&J executive to its board

Wed, 12 Aug 2026 08:00:58 -0400

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has appointed John C. Reed, M.D., Ph.D., to its board of directors, the company announced Aug. 12, 2026.

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed John C. Reed, M.D., Ph.D., to its Board of Directors.

Dr. Reed currently serves as Executive Vice President, Innovative Medicine, Research & Development at Johnson & Johnson (“J&J”) and is a member of J&J’s Executive Committee, where he leads research and development across oncology, immunology, neuroscience and other areas of significant unmet medical need.

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors

Wed, 12 Aug 2026 08:00:00 -0400

Julian Baker, Chairman of the Board of Directors of Madrigal, stated,

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:05:00 -0400

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on August 1, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,263 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,263 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,263 time-based restricted

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Thu, 06 Aug 2026 16:05:00 -0400

The equity awards were granted as an inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 4,263 time-based restricted

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Thu, 06 Aug 2026 08:00:00 -0400

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46th Annual Growth Conference on Tuesday, Aug. 11, 2026 at 12:00 P.M. EDT.

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Thu, 06 Aug 2026 08:00:00 -0400

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Thu, 06 Aug 2026 08:00:00 -0400

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.

Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference

Thu, 06 Aug 2026 08:00:00 -0400

The presentation will be webcast live and may be accessed here or by visiting Madrigal’s Investor Relations Events and Presentations page. A replay of the webcast will be available after the event.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

The analyst comments "Stock overcorrected on perception of 'F4 data coming late or coming delayed' (but a delay could be a long-term positive). Q2 beat also confirmed net-zero volume impact from Novo, setting up for consecutive revisions 2026-2027. Upgrading MDGL to OP."

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Wolfe Research Upgrades Madrigal Pharmaceuticals (MDGL) to Outperform

Tue, 04 Aug 2026 05:08:02 -0400

(Updated - August 4, 2026 5:08 AM EDT)

Wolfe Research analyst Andy Chen upgraded Madrigal Pharmaceuticals (NASDAQ: MDGL) from Peerperform to Outperform with a price target of $605.00.

For an analyst ratings summary and ratings history on Madrigal Pharmaceuticals click here. For more ratings news on Madrigal Pharmaceuticals click here.

Shares of Madrigal Pharmaceuticals closed at $482.00 yesterday.

Madrigal Pharmaceuticals (MDGL) PT Lowered to $962 at Barclays

Mon, 03 Aug 2026 06:40:33 -0400

Barclays analyst Eliana Merle lowered the price target on Madrigal Pharmaceuticals (NASDAQ: MDGL) to $962.00 (from $964.00) while maintaining a Overweight rating.

Madrigal Pharma (MDGL) Tops Q2 EPS by 76c

Fri, 31 Jul 2026 09:18:28 -0400

Madrigal Pharma (NASDAQ: MDGL) reported Q2 EPS of ($1.99), $0.76 better than the analyst estimate of ($2.75). Revenue for the quarter came in at $364.3 million versus the consensus estimate of $349.15 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

H.C. Wainwright Reiterates Buy Rating on Madrigal Pharmaceuticals (MDGL)

Fri, 31 Jul 2026 06:42:01 -0400

H.C. Wainwright analyst Andrew Fein reiterated a Buy rating and $620.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).

The analyst commented: "Rezdiffra is now nine quarters into its commercial launch and continues to generate impressive growth, with 2Q26 net sales of $364.3M, up 71% YoY. Importantly, the F2–F3 addressable population continues to expand, growing nearly 50% over two years to approximately 460K patients by YE25. We continue to view this as a massively underpenetrated opportunity, with only approximately 10% of MASH patients diagnosed and Rezdiffra reaching only approximately 10% of the currently addressable population, according to our estimates. Ultimately, we believe